PofoliaShared via Pofolia

Journal of Clinical Medicine· 2026Q2

Oral Lichen Planus: Current Evidence, Clinical Challenges, and the Search for Optimal Management

Masanobu Abe

Short summary

Oral lichen planus (OLP) management remains challenging due to its chronic, refractory nature, with topical corticosteroids as the primary treatment, supplemented by calcineurin inhibitors or laser therapy for refractory cases. Long-term surveillance is crucial as OLP is considered a potentially malignant disorder.

AI-generated from the title and abstract; the full text is not read.

Key points

  • OLP diagnosis relies on clinical findings and histopathology, differentiating it from similar conditions like lichenoid lesions and autoimmune blistering diseases.
  • Topical corticosteroids are the primary treatment for OLP, with topical calcineurin inhibitors and laser therapy as alternatives for steroid-refractory or specific cases.
  • Systemic corticosteroids are reserved for severe, extensive, or refractory OLP.
  • OLP is considered a potentially malignant disorder, necessitating long-term surveillance for oral squamous cell carcinoma development.
  • Optimal OLP management requires an individualized approach integrating diagnosis, factor elimination, oral hygiene, therapy selection, and surveillance.

AI-generated from the title and abstract; the full text is not read.

Abstract

Oral lichen planus (OLP) is a chronic, immune-mediated inflammatory disease of the oral mucosa with an incompletely understood etiology and a diverse clinical presentation. Because OLP is often refractory and follows a chronic or relapsing course, accurate diagnosis and appropriate long-term management remain important clinical challenges. The diagnosis of OLP is based on clinical findings and histopathological examination, with consideration of a variety of conditions that may mimic OLP, including oral lichenoid lesions, autoimmune blistering diseases, candidiasis, and leukoplakia. Management is primarily aimed at controlling inflammation and alleviating symptoms. Elimination of precipitating or aggravating factors, improvement of oral hygiene, and appropriate dental treatment are important components of long-term disease management. Topical corticosteroids remain the mainstay of local therapy, while topical calcineurin inhibitors, such as tacrolimus and pimecrolimus, may provide useful alternatives, particularly in steroid-refractory cases. Laser therapy may also be considered as an adjunctive treatment in selected patients. Systemic corticosteroids are generally reserved for severe, extensive, or refractory disease. In addition, various adjunctive and alternative therapies, including herbal medicines, phytochemicals, vitamins, micronutrients, hydroxychloroquine, and methotrexate, have been investigated. Although several of these approaches have shown promising therapeutic effects, the available evidence remains limited and further high-quality clinical studies are required. OLP is currently classified among the oral potentially malignant disorders, although the magnitude of its malignant transformation risk remains debated. Therefore, long-term surveillance is important because some patients may develop oral squamous cell carcinoma. At present, the management of OLP focuses primarily on symptom relief and disease control rather than cure. A comprehensive and individualized approach that integrates accurate diagnosis, elimination of aggravating factors, oral health management, appropriate selection of topical and systemic therapies, and long-term surveillance is therefore important. Further clarification of the underlying mechanisms of OLP and well-designed clinical studies may contribute to more effective and individualized approaches to its diagnosis and management.

The authors' abstract, as published at the source. Journal of Clinical Medicine, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Periodontics

PeriodonticsDentistry